Our research sheds light on the mechanisms by which MARCO governs MHC‐I molecules to alter TAMs' capacity for antigen cross‐presentation, suggesting a potential therapeutic target for RCC by modulating tumor‐associated macrophage reprogramming and restoring immune surveillance. This evidence concerns the gene MARCO and renal cell adenocarcinoma.